Testing a web-based decision aid for genomic results in rare cancers
Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid
This study is testing a new online tool to help patients with rare cancers, especially African Americans, make better choices about their genomic test results.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 240 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Washington University School of Medicine Academic / other |
| Locations | 1 site (St Louis, Missouri) |
| Trial ID | NCT06910670 on ClinicalTrials.gov |
What this trial studies
This randomized control trial evaluates the effectiveness of a modified web-based decision aid designed to assist patients in making informed choices about genomic testing results related to rare cancers. Participants will either use the new decision aid or a standard control to guide their decisions on the type of genomic results they wish to receive. The study focuses on patients diagnosed with cholangiocarcinoma, colorectal cancer, or multiple myeloma, particularly among African American individuals. The goal is to enhance patient engagement and understanding of genomic information.
Who should consider this trial
Good fit: Ideal candidates include adults diagnosed with cholangiocarcinoma, multiple myeloma (specifically African American), or colorectal cancer (African American and aged 65 or older).
Not a fit: Patients without a diagnosis of the specified cancers or those who do not meet the demographic criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could empower patients with rare cancers to make more informed decisions regarding their genomic testing options.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in enhancing patient decision-making through web-based tools.
Eligibility criteria
Show full inclusion / exclusion criteria
Eligibility Criteria: * Enrolled in the WU-PE-CGS study (IRB#202106129); that eligibility entails: * Diagnosis of cholangiocarcinoma * Diagnosis of multiple myeloma, must be African American * Diagnosis of colorectal cancer, must be African American and age 65 or older at time of diagnosis * At least 18 years old. * Able to understand an IRB-approved informed consent document and agree to participation * Have access to a personal computer, tablet or mobile device
Where this trial is running
St Louis, Missouri
- Washington University School of Medicine — St Louis, Missouri, United States (Recruiting)
Study contacts
- Principal investigator: Erin Linnenbringer, Ph.D., MS — Washington University School of Medicine
- Study coordinator: Erin Linnenbringer, Ph.D., MS
- Email: elinnen@wustl.edu
- Phone: 314-747-1966
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.